STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1541 by analyst upside · 2026-08-13
COGT
Cogent Biosciences, Inc.
Healthcare · Market Cap $7B · P/E 0x
ANALYST PRICE TARGET
+39.2%
implied upside to consensus target
Current Price $38.98
Consensus Target $54.25
Bull Target $72.0
Bear Target $35.0
Analysts Covering 12
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
8
Hold
2
Sell
0
52-Week Low $11.41
52-Week High $43.73
YTD Return +12.2%
FUNDAMENTALS
Market Cap $7B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.16
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $11.41
52-Week High $43.73
Current Price $38.98
Bear Target $35.0
Bull Target $72.0
● Now $38.98 ● Target $54.25
TRADING DATA
Avg Volume 2.5M
YTD Return +12.2%
Analyst Count 12
Consensus Buy
Upside to Target +39.2%
Last Updated 2026-08-13

ANALYST SUMMARY

Cogent Biosciences, Inc. (COGT) is currently trading at $38.98 with a Wall Street consensus price target of $54.25, implying potential upside of 39.2% over the next 12 months. 12 analysts currently cover COGT, with a consensus rating of Buy - 83% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $72.0, while the most cautious has a target of $35.0.

COGT operates in the Healthcare sector with a market capitalisation of $7B. The stock is up 12.2% year-to-date and is currently trading near the upper end of its 52-week range of $11.41 – $43.73.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for COGT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wedbush reit
Outperform → Outperform 2026-05-29 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-05-06 31% win rate (48 calls)
Wedbush reit
Outperform → Outperform 2026-03-17 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2026-02-18 14% win rate (7 calls)
Wedbush reit
Outperform → Outperform 2026-01-21 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-01-06 31% win rate (48 calls)
JP Morgan - Reiterated
Overweight → Overweight 2025-12-19 43% win rate (7 calls)
Needham reit
Hold → Hold 2025-12-08 20% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
53
out of 100
Coverage depth
20/30
Consensus clarity
11/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →